Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q3 FY25 results · Oct–Dec 2024
Tatva Chintan Pharma Chem reported revenue from operations of ₹85.90 crore (up 2.0% from Q3 FY24) and net profit of ₹0.14 crore (down 96.0% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 85.90 | 84.21 | +2.0% | 83.49 | +2.9% |
| Other income | 0.04 | 1.21 | −96.4% | 0.38 | −88.3% |
| Total income | 85.94 | 85.42 | +0.6% | 83.87 | +2.5% |
| Profit before tax | (0.23) | 5.24 | Turned loss | (1.02) | Loss narrowed |
| Net profit for the period | 0.14 | 3.46 | −96.0% | (0.66) | Turned profit |
| EPS, basic (₹) | 0.06 | 1.48 | −95.9% | (0.29) | Turned profit |
| Net margin (%) | 0.2 | 4.1 | -0.8 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 84.00 | 86.07 | −2.4% | 80.96 | +3.8% |
| Other income | 0.04 | 1.21 | −96.7% | 0.81 | −95.0% |
| Total income | 84.04 | 87.28 | −3.7% | 81.77 | +2.8% |
| Profit before tax | (1.65) | 6.56 | Turned loss | (1.58) | Loss widened |
| Net profit for the period | (1.17) | 4.65 | Turned loss | (1.11) | Loss widened |
| EPS, basic (₹) | (0.50) | 1.99 | Turned loss | (0.47) | Loss widened |
| Net margin (%) | -1.4 | 5.4 | -1.4 |
Consolidated
- Filed with BSE
- 29 Jan 2025, 13:46 IST
- Board meeting
- 28 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Jan 2025, 13:46 IST
- Board meeting
- 28 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE